Title : The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.

Pub. Date : 2012

PMID : 22783588






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 METHODS: A549 (EGFR wild-type and KRAS mutation) and H1975 (EGFR mutation and KRAS wild-type) cell lines were treated with pemetrexed and/or sorafenib in vitro. Pemetrexed KRAS proto-oncogene, GTPase Homo sapiens